MCID: UTR011
MIFTS: 46

Uterine Corpus Serous Adenocarcinoma

Categories: Cancer diseases, Reproductive diseases

Aliases & Classifications for Uterine Corpus Serous Adenocarcinoma

MalaCards integrated aliases for Uterine Corpus Serous Adenocarcinoma:

Name: Uterine Corpus Serous Adenocarcinoma 12 15
Uterine Papillary Serous Carcinoma 12
Endometrial Serous Adenocarcinoma 74
Uterine Serous Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:5750
NCIt 51 C27838
UMLS 74 C1336921

Summaries for Uterine Corpus Serous Adenocarcinoma

Disease Ontology : 12 A uterine corpus cancer that is characterized histologically by papillae with fibrovascular cores, marked nuclear atypia, psammoma bodies and cilia.

MalaCards based summary : Uterine Corpus Serous Adenocarcinoma, also known as uterine papillary serous carcinoma, is related to adenocarcinoma and carcinosarcoma. An important gene associated with Uterine Corpus Serous Adenocarcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are TGF-Beta Pathway and Class I MHC mediated antigen processing and presentation. The drugs Paclitaxel and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include lymph node, endothelial and cervix, and related phenotypes are Decreased CDKN1A mRNA expression and Decreased CDKN1A mRNA expression

Related Diseases for Uterine Corpus Serous Adenocarcinoma

Diseases related to Uterine Corpus Serous Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 100)
# Related Disease Score Top Affiliating Genes
1 adenocarcinoma 30.4 ERBB2 PIK3CA TP53
2 carcinosarcoma 30.2 ERBB2 PIK3CA TP53
3 endometrial cancer 29.7 BRCA1 CCNE1 ERBB2 PIK3CA TP53
4 ovarian cancer 1 29.6 BRCA1 ERBB2 PIK3CA TP53
5 ovarian cancer 29.4 BRCA1 ERBB2 PIK3CA TP53
6 uterine carcinosarcoma 29.2 ERBB2 FBXW7 PIK3CA PPP2R1A TP53
7 breast cancer 28.7 BRCA1 CCNE1 ERBB2 FBXW7 PIK3CA TP53
8 gastric papillary adenocarcinoma 10.3 ERBB2 TP53
9 papillary adenocarcinoma 10.3 ERBB2 TP53
10 pleomorphic adenoma carcinoma 10.3 ERBB2 TP53
11 non-proliferative fibrocystic change of the breast 10.3 ERBB2 TP53
12 glioma susceptibility 1 10.3 ERBB2 TP53
13 microglandular adenosis 10.3 ERBB2 TP53
14 esophagus adenocarcinoma 10.3 ERBB2 TP53
15 adult hepatocellular carcinoma 10.2 PIK3CA TP53
16 rare adenocarcinoma of the breast 10.2 PIK3CA TP53
17 malignant spiradenoma 10.2 PIK3CA TP53
18 prostate squamous cell carcinoma 10.2 PPP2R1A TP53
19 breast benign neoplasm 10.2 ERBB2 TP53
20 thoracic benign neoplasm 10.2 ERBB2 TP53
21 granulosa cell tumor of the ovary 10.2 ERBB2 TP53
22 hidradenocarcinoma 10.2 ERBB2 TP53
23 tonsil cancer 10.2 ERBB2 TP53
24 acneiform dermatitis 10.2 ERBB2 PIK3CA
25 barrett's adenocarcinoma 10.2 ERBB2 TP53
26 epithelial-myoepithelial carcinoma 10.1 FBXW7 TP53
27 tuberculous salpingitis 10.1 BRCA1 ERBB2
28 adenosquamous lung carcinoma 10.1 ERBB2 PIK3CA
29 synchronous bilateral breast carcinoma 10.1 BRCA1 TP53
30 papillary serous adenocarcinoma 10.1 BRCA1 TP53
31 breast medullary carcinoma 10.1 BRCA1 ERBB2
32 glycogen-rich clear cell breast carcinoma 10.1 BRCA1 TP53
33 esophageal disease 10.1 ERBB2 TP53
34 penile cancer 10.1 PIK3CA TP53
35 fallopian tube adenocarcinoma 10.1 BRCA1 ERBB2
36 brain stem glioma 10.1 PIK3CA TP53
37 lobular neoplasia 10.1 BRCA1 ERBB2
38 mixed cell type cancer 10.1 ERBB2 PPP2R1A TP53
39 insulin-like growth factor i 10.1
40 pulmonary fibrosis 10.1
41 ovarian serous carcinoma 10.1
42 lymphoma 10.1
43 thrombocytosis 10.1
44 endometrial adenocarcinoma 10.1
45 cervix carcinoma 10.1
46 breast squamous cell carcinoma 10.1 ERBB2 PIK3CA TP53
47 mutagen sensitivity 10.1 BRCA1 TP53
48 ovary adenocarcinoma 10.1 ERBB2 PIK3CA TP53
49 adenosquamous carcinoma 10.0 PIK3CA TP53
50 bilateral breast cancer 10.0 BRCA1 ERBB2

Graphical network of the top 20 diseases related to Uterine Corpus Serous Adenocarcinoma:



Diseases related to Uterine Corpus Serous Adenocarcinoma

Symptoms & Phenotypes for Uterine Corpus Serous Adenocarcinoma

GenomeRNAi Phenotypes related to Uterine Corpus Serous Adenocarcinoma according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased CDKN1A mRNA expression GR00389-S-1 9.13 FBXW7 TP53
2 Decreased CDKN1A mRNA expression GR00389-S-2 9.13 TP53
3 Increased cell death HMECs cells GR00103-A-0 9.02 BRCA1 FBXW7 PIK3CA PPP2R1A TP53

MGI Mouse Phenotypes related to Uterine Corpus Serous Adenocarcinoma:

47 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.04 BRCA1 CCNE1 ERBB2 FBXW7 KIAA1324 PIK3CA
2 behavior/neurological MP:0005386 10 BRCA1 CCNE1 ERBB2 PIK3CA PPP2R1A TP53
3 cardiovascular system MP:0005385 9.99 BRCA1 CCNE1 ERBB2 FBXW7 PIK3CA TP53
4 growth/size/body region MP:0005378 9.95 BRCA1 CCNE1 ERBB2 FBXW7 PIK3CA PPP2R1A
5 embryo MP:0005380 9.93 BRCA1 CCNE1 ERBB2 FBXW7 PIK3CA TP53
6 endocrine/exocrine gland MP:0005379 9.91 BRCA1 CCNE1 ERBB2 FBXW7 PIK3CA TP53
7 homeostasis/metabolism MP:0005376 9.91 BRCA1 ERBB2 FBXW7 KIAA1324 PIK3CA PPP2R1A
8 digestive/alimentary MP:0005381 9.88 BRCA1 CCNE1 ERBB2 FBXW7 TP53
9 mortality/aging MP:0010768 9.86 BRCA1 CCNE1 ERBB2 FBXW7 KIAA1324 PIK3CA
10 integument MP:0010771 9.8 BRCA1 CCNE1 ERBB2 FBXW7 PIK3CA TP53
11 neoplasm MP:0002006 9.7 BRCA1 CCNE1 ERBB2 FBXW7 PIK3CA PPP2R1A
12 normal MP:0002873 9.43 BRCA1 CCNE1 ERBB2 FBXW7 PPP2R1A TP53
13 reproductive system MP:0005389 9.1 BRCA1 CCNE1 ERBB2 KIAA1324 PIK3CA TP53

Drugs & Therapeutics for Uterine Corpus Serous Adenocarcinoma

Drugs for Uterine Corpus Serous Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 88)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
2
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 38904 10339178 498142
3
Lenograstim Approved, Investigational Phase 3,Phase 1 135968-09-1
4
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 441203 84093 2767
5
Doxorubicin Approved, Investigational Phase 3,Phase 1 23214-92-8 31703
6
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3 22916-47-8 4189
7
Sirolimus Approved, Investigational Phase 2, Phase 3 53123-88-9 46835353 6436030 5284616
8
Everolimus Approved Phase 2, Phase 3 159351-69-6 6442177 70789204
9
Metformin Approved Phase 2, Phase 3 657-24-9 14219 4091
10
Letrozole Approved, Investigational Phase 2, Phase 3 112809-51-5 3902
11
Doxil Approved June 1999 Phase 3,Phase 1 31703
12 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
13 Antimitotic Agents Phase 3,Phase 2,Phase 1
14 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
15 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
16 Adjuvants, Immunologic Phase 3,Phase 1
17 Immunologic Factors Phase 3,Phase 2,Phase 1
18 Topoisomerase Inhibitors Phase 3,Phase 1
19 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
20 Anti-Infective Agents Phase 2, Phase 3,Phase 1
21 Immunosuppressive Agents Phase 2, Phase 3
22 Antifungal Agents Phase 2, Phase 3
23 Hypoglycemic Agents Phase 2, Phase 3
24 Aromatase Inhibitors Phase 2, Phase 3
25 Estrogen Receptor Antagonists Phase 2, Phase 3
26 Estrogen Antagonists Phase 2, Phase 3
27 Hormones Phase 2, Phase 3
28 Steroid Synthesis Inhibitors Phase 2, Phase 3
29 Hormone Antagonists Phase 2, Phase 3
30 Estrogens Phase 2, Phase 3
31 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3
32
Bevacizumab Approved, Investigational Phase 2,Phase 1 216974-75-3
33
Nintedanib Approved Phase 2 656247-17-5 56843413
34
afatinib Approved Phase 2 850140-72-6, 439081-18-2 10184653
35
Doxycycline Approved, Investigational, Vet_approved Phase 2 564-25-0 54671203
36
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
37
Olaparib Approved Phase 2 763113-22-0 23725625
38
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
39
Cediranib Investigational Phase 2 288383-20-0 9933475
40
SB-649868 Experimental, Investigational Phase 2 110-16-7, 110-17-8 444972
41
Trebananib Investigational Phase 2 894356-79-7
42
MK-1775 Investigational Phase 2 501-36-0, 955365-80-7 24856436 445154
43 Imatinib Mesylate Phase 1, Phase 2 220127-57-1 123596
44 Protein Kinase Inhibitors Phase 1, Phase 2,Phase 2
45 Angiogenesis Inhibitors Phase 2,Phase 1
46 Immunoglobulins Phase 2,Phase 1
47 Angiogenesis Modulating Agents Phase 2,Phase 1
48 Antibodies, Monoclonal Phase 2,Phase 1
49 Antineoplastic Agents, Immunological Phase 2,Phase 1
50 Immunoglobulin G Phase 2,Phase 1

Interventional clinical trials:

(show all 43)
# Name Status NCT ID Phase Drugs
1 Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer Completed NCT00006011 Phase 3 Doxorubicin Hydrochloride;Cisplatin;Paclitaxel
2 Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol Recruiting NCT02501954 Phase 3 Cisplatin;Carboplatin;Paclitaxel
3 Short Course Vaginal Cuff Brachytherapy in Treating Patients With Stage I-II Endometrial Cancer Recruiting NCT03422198 Phase 3
4 Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation Active, not recruiting NCT03285802 Phase 2, Phase 3 Letrozole;Everolimus
5 Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer Active, not recruiting NCT02065687 Phase 2, Phase 3 Carboplatin;Metformin Hydrochloride;Paclitaxel
6 Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer Active, not recruiting NCT00942357 Phase 3 Carboplatin;Cisplatin;Paclitaxel
7 Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer Active, not recruiting NCT00807768 Phase 3 Carboplatin;Paclitaxel
8 Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation Therapy in Treating Patients With Stage IIIC-IV Uterine Cancer Unknown status NCT02112552 Phase 2 Paclitaxel;Carboplatin
9 Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma Completed NCT00506779 Phase 1, Phase 2 Imatinib Mesylate;Paclitaxel
10 A Study of Radiation Therapy and Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma Completed NCT00231868 Phase 2 Carboplatin and Paclitaxel and Pelvic Radiation Therapy;Carboplatin and Paclitaxel and Radiation Therapy
11 Paclitaxel in Treating Patients With Refractory or Recurrent Endometrial Cancer Completed NCT00022620 Phase 2 paclitaxel
12 Uterine Papillary Serous Cancer (UPSC) Trial Completed NCT00147680 Phase 2 Paclitaxel, Carboplatin
13 Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer Completed NCT01307631 Phase 2 Akt Inhibitor MK2206
14 Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01132820 Phase 2 Cediranib Maleate
15 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
16 Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01225887 Phase 2 Nintedanib
17 Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer Completed NCT01005329 Phase 2 Carboplatin;Cisplatin;Paclitaxel
18 Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01642082 Phase 2
19 Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer Completed NCT01210222 Phase 2
20 Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT00888173 Phase 2 Brivanib Alaninate
21 A Phase II Evaluation of Afatinibin Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma Recruiting NCT02491099 Phase 2 Afatinib
22 AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma Recruiting NCT03668340 Phase 2 AZD1775
23 Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer Recruiting NCT02874430 Phase 2 Metformin Hydrochloride;Doxycycline
24 Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer Recruiting NCT00492778 Phase 2 Cisplatin
25 Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer Active, not recruiting NCT02728258 Phase 2 Copanlisib
26 Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer Active, not recruiting NCT01935934 Phase 2 Cabozantinib S-malate
27 Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer Active, not recruiting NCT00478426 Phase 2 Sunitinib Malate
28 Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer Active, not recruiting NCT00977574 Phase 2 Carboplatin;Ixabepilone;Paclitaxel;Temsirolimus
29 Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer Not yet recruiting NCT03836157 Phase 2 Mirvetuximab Soravtansine;Bevacizumab
30 Olaparib and Cediranib Maleate in Treating Patients With Recurrent, Refractory, or Metastatic Endometrial Cancer Suspended NCT03660826 Phase 2 Cediranib Maleate;Olaparib
31 A Pilot Study of Celecoxib in Patients With Grade 2 or 3 Uterine Cancers Terminated NCT00231829 Phase 2 Celecoxib
32 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer Completed NCT00005840 Phase 1 Paclitaxel;Cisplatin
33 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer Completed NCT00005830 Phase 1 Doxorubicin Hydrochloride;Cisplatin
34 Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer Completed NCT01440998 Phase 1 Carboplatin;Dasatinib;Paclitaxel
35 Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer Completed NCT00575952 Phase 1 Cisplatin;Doxorubicin Hydrochloride;Paclitaxel
36 Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Primary Ovarian or Uterine Cancer Recruiting NCT03325634 Phase 1
37 Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Recruiting NCT03552471 Phase 1 Rucaparib Camsylate
38 Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer Active, not recruiting NCT01935973 Phase 1 Trametinib;Uprosertib
39 TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors Active, not recruiting NCT02142803 Phase 1 Sapanisertib
40 VSV-hIFNbeta-NIS in Treating Patients With Stage IV or Recurrent Endometrial Cancer Suspended NCT03120624 Phase 1 Technetium Tc-99m Sodium Pertechnetate
41 PET/CT and Lymph Node Mapping in Finding Lymph Node Metastasis in Patients With High-Risk Endometrial Cancer Active, not recruiting NCT01737619 Not Applicable Indocyanine Green Solution
42 Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery Active, not recruiting NCT02315469
43 Biomarkers in Blood and Tissue Samples From Patients With Uterine Cancer Not yet recruiting NCT01344837

Search NIH Clinical Center for Uterine Corpus Serous Adenocarcinoma

Genetic Tests for Uterine Corpus Serous Adenocarcinoma

Anatomical Context for Uterine Corpus Serous Adenocarcinoma

MalaCards organs/tissues related to Uterine Corpus Serous Adenocarcinoma:

42
Lymph Node, Endothelial, Cervix

Publications for Uterine Corpus Serous Adenocarcinoma

Articles related to Uterine Corpus Serous Adenocarcinoma:

(show top 50) (show all 155)
# Title Authors Year
1
Can morphometric analysis of the fallopian tube fimbria predict the presence of uterine papillary serous carcinoma (UPSC)? ( 30818325 )
2019
2
Cancer Antigen 125 Levels are Significantly Associated With Prognostic Parameters in Uterine Papillary Serous Carcinoma. ( 29958235 )
2018
3
Clinicopathological and survival analysis of uterine papillary serous carcinoma: a single institutional review of 106 cases. ( 30464593 )
2018
4
Extrauterine Spread, Adjuvant Treatment, and Prognosis in Noninvasive Uterine Papillary Serous Carcinoma of the Endometrium: A Retrospective Multicenter Study. ( 27668395 )
2017
5
Sonographic depiction of non-palpable uterine papillary serous carcinoma metastasis embedded within the abdominal wall. ( 27683188 )
2017
6
Prior breast cancer and tamoxifen exposure does not influence outcomes in women with uterine papillary serous carcinoma. ( 28062116 )
2017
7
Utility of radiation therapy for early-stage uterine papillary serous carcinoma. ( 28343693 )
2017
8
Comparative Survival Outcomes of Uterine Papillary Serous Carcinoma, Clear Cell Carcinoma, Grade 3 Endometrioid Adenocarcinoma, and Carcinosarcoma of Endometrial Cancer in Rajavithi Hospital. ( 27266220 )
2016
9
The impact of combined radiation and chemotherapy on outcome in uterine papillary serous carcinoma compared to chemotherapy alone. ( 26463437 )
2016
10
Clinical Significance of Positive Pelvic Washings in Uterine Papillary Serous Carcinoma Confined to an Endometrial Polyp. ( 26535985 )
2016
11
Survival advantage associated with multimodal therapy in women with node-positive (stage-IIIC) uterine papillary serous carcinoma: a National Cancer Database study. ( 26537059 )
2016
12
Uterine Papillary Serous Carcinoma: A Single-Institution Review of 62 Cases. ( 26588230 )
2016
13
Adrenal Metastasis from Uterine Papillary Serous Carcinoma. ( 27117594 )
2016
14
Analysis of clinical and pathological characteristics, treatment methods, survival, and prognosis of uterine papillary serous carcinoma. ( 27514313 )
2016
15
Identification of a preoperative predictive factor for lymph node metastasis in uterine papillary serous carcinoma: long-term results from a single institution. ( 25470688 )
2015
16
Adjuvant vaginal brachytherapy decreases the risk of vaginal recurrence in patients with stage I non-invasive uterine papillary serous carcinoma. A multi-institutional study. ( 25575483 )
2015
17
Impact of adjuvant chemotherapy and pelvic radiation on pattern of recurrence and outcome in stage I non-invasive uterine papillary serous carcinoma. A multi-institution study. ( 25641568 )
2015
18
Outcome of recurrent uterine papillary serous carcinoma treated with platinum-based chemotherapy. ( 25695549 )
2015
19
Uterine papillary serous carcinoma pre-operatively diagnosed as endometrioid carcinoma: Is omentectomy necessary? ( 26235227 )
2015
20
Clinical predictors of long-term survival for stage IVB uterine papillary serous carcinoma confined to the abdomen. ( 24211401 )
2014
21
Case of uterine papillary serous carcinoma following tamoxifen treatment that could not be diagnosed during screening. ( 24606575 )
2014
22
Abdominal wall metastasis of uterine papillary serous carcinoma in a post-menopausal woman: a case report. ( 25371890 )
2014
23
Pulmonary fibrosis after pegylated liposomal Doxorubicin in a patient with uterine papillary serous carcinoma. ( 23358980 )
2013
24
Decreased expression of 14-3-3I8 is predictive of poor prognosis for patients with human uterine papillary serous carcinoma. ( 24201220 )
2013
25
A prospective phase II study of chemoradiation followed by adjuvant chemotherapy for FIGO stage I-IIIA (1988) uterine papillary serous carcinoma of the endometrium. ( 23385150 )
2013
26
Patterns of relapse in stage I-II uterine papillary serous carcinoma treated with adjuvant intravaginal radiation (IVRT) with or without chemotherapy. ( 24055615 )
2013
27
Excellent Response to Palliative Chemotherapy for Pleural Recurrence of Uterine Papillary Serous Carcinoma. ( 29147358 )
2013
28
Preoperative CA-125 predicts extra-uterine disease and survival in uterine papillary serous carcinoma patients. ( 22865295 )
2012
29
Phase II trial of adjuvant pelvic radiation "sandwiched" between combination paclitaxel and carboplatin in women with uterine papillary serous carcinoma. ( 22035806 )
2012
30
Prognostic determinants in patients with stage I uterine papillary serous carcinoma: a 15-year multi-institutional review. ( 22237383 )
2012
31
Clinicopathological and prognostic impact of human epidermal growth factor receptor type 2 (HER2) and hormone receptor expression in uterine papillary serous carcinoma. ( 22329832 )
2012
32
Endometrial serous carcinoma (uterine papillary serous carcinoma): precancerous lesions and the theoretical promise of a preventive approach. ( 22679564 )
2012
33
Analysis of treatment failures and survival of patients with uterine papillary serous carcinoma: a Cooperation Task Force (CTF) Study. ( 22976496 )
2012
34
Her-2 targeting in uterine papillary serous carcinoma. ( 24371631 )
2012
35
Prospective, non-randomized phase 2 clinical trial of carboplatin plus paclitaxel with sequential radical pelvic radiotherapy for uterine papillary serous carcinoma. ( 21126755 )
2011
36
Clinical management of uterine papillary serous carcinoma. ( 21166512 )
2011
37
Performance of serum CA125 as a prognostic biomarker in patients with uterine papillary serous carcinoma. ( 21436701 )
2011
38
Optimal surgical debulking in uterine papillary serous carcinoma affects survival. ( 21440290 )
2011
39
Uterine papillary serous carcinoma. ( 21508697 )
2011
40
Abnormal cervical cytology in the diagnosis of uterine papillary serous carcinoma: earlier detection of a poor prognostic cancer subtype? ( 21525737 )
2011
41
Clinicopathological characteristics and her-2/neu status in chinese patients with uterine papillary serous carcinoma. ( 21647234 )
2011
42
The importance of chemotherapy and radiation in uterine papillary serous carcinoma. ( 21963091 )
2011
43
[Clinical significance of Her-2/neu status in patients with uterine papillary serous carcinoma]. ( 20646447 )
2010
44
Uterine papillary serous carcinoma: epidemiology, pathogenesis and management. ( 19952744 )
2010
45
Retroperitoneal tuberculosis in a patient with uterine papillary serous carcinoma. ( 20060636 )
2010
46
Intraperitoneal radioactive phosphorus (32P) and vaginal brachytherapy as adjuvant treatment for uterine papillary serous carcinoma and clear cell carcinoma: the Indiana University experience. ( 20129252 )
2010
47
Prognostic determinants in patients with stage IIIC and IV uterine papillary serous carcinoma. ( 20691465 )
2010
48
Long-term survival in uterine clear cell carcinoma and uterine papillary serous carcinoma. ( 20944161 )
2010
49
Uterine papillary serous carcinoma metastatic to the choroid. ( 25390124 )
2010
50
Synuclein-gamma (SNCG) may be a novel prognostic biomarker in uterine papillary serous carcinoma. ( 19476987 )
2009

Variations for Uterine Corpus Serous Adenocarcinoma

Copy number variations for Uterine Corpus Serous Adenocarcinoma from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 52344 11 16200000 21700000 Copy number SAA Uterine serous papillary cancer

Expression for Uterine Corpus Serous Adenocarcinoma

Search GEO for disease gene expression data for Uterine Corpus Serous Adenocarcinoma.

Pathways for Uterine Corpus Serous Adenocarcinoma

Pathways related to Uterine Corpus Serous Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 50)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.32 BRCA1 ERBB2 PIK3CA PPP2R1A TP53
2
Show member pathways
13.23 ERBB2 FBXW7 PIK3CA PPP2R1A TP53
3
Show member pathways
12.77 BRCA1 CCNE1 PPP2R1A TP53
4
Show member pathways
12.66 CCNE1 ERBB2 PIK3CA TP53
5 12.63 CCNE1 ERBB2 PIK3CA TP53
6
Show member pathways
12.52 ERBB2 PIK3CA PPP2R1A TP53
7
Show member pathways
12.51 BRCA1 CCNE1 FBXW7 TP53
8
Show member pathways
12.47 BRCA1 CCNE1 ERBB2 PIK3CA TP53
9
Show member pathways
12.47 BRCA1 CCNE1 ERBB2 PIK3CA PPP2R1A TP53
10
Show member pathways
12.43 BRCA1 CCNE1 ERBB2 PIK3CA TP53
11
Show member pathways
12.42 ERBB2 PIK3CA TP53
12
Show member pathways
12.42 ERBB2 PIK3CA TP53
13
Show member pathways
12.4 CCNE1 PPP2R1A TP53
14
Show member pathways
12.33 ERBB2 PIK3CA TP53
15 12.3 BRCA1 CCNE1 PPP2R1A TP53
16
Show member pathways
12.27 PIK3CA PPP2R1A TP53
17
Show member pathways
12.27 ERBB2 PIK3CA TP53
18
Show member pathways
12.24 CCNE1 FBXW7 TP53
19
Show member pathways
12.21 BRCA1 CCNE1 TP53
20
Show member pathways
12.18 CCNE1 PPP2R1A TP53
21
Show member pathways
12.18 CCNE1 PIK3CA PPP2R1A
22 12.13 BRCA1 CCNE1 ERBB2 PIK3CA TP53
23 12.12 ERBB2 PIK3CA TP53
24 12.12 CCNE1 PIK3CA TP53
25
Show member pathways
12.07 BRCA1 CCNE1 TP53
26
Show member pathways
12.05 BRCA1 CCNE1 FBXW7
27
Show member pathways
12.04 ERBB2 PIK3CA TP53
28 11.99 CCNE1 PIK3CA TP53
29 11.96 ERBB2 PIK3CA TP53
30
Show member pathways
11.86 ERBB2 PIK3CA TP53
31 11.82 PIK3CA PPP2R1A TP53
32 11.79 ERBB2 PIK3CA TP53
33 11.69 CCNE1 PIK3CA TP53
34
Show member pathways
11.65 BRCA1 CCNE1 TP53
35 11.48 ERBB2 PIK3CA TP53
36
Show member pathways
11.45 CCNE1 ERBB2 PIK3CA
37 11.44 PIK3CA TP53
38 11.41 BRCA1 TP53
39 11.41 CCNE1 TP53
40 11.39 CCNE1 TP53
41 11.36 BRCA1 TP53
42 11.3 BRCA1 CCNE1 TP53
43 11.16 ERBB2 PIK3CA
44 11.16 BRCA1 TP53
45 11.14 BRCA1 CCNE1 TP53
46 11.12 BRCA1 ERBB2 PIK3CA TP53
47 11.01 BRCA1 CCNE1 TP53
48 10.84 BRCA1 ERBB2 FBXW7 PIK3CA TP53
49 10.78 BRCA1 CCNE1 TP53
50 10.21 CCNE1 TP53

GO Terms for Uterine Corpus Serous Adenocarcinoma

Biological processes related to Uterine Corpus Serous Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 androgen receptor signaling pathway GO:0030521 9.37 BRCA1 CCNE1
2 phosphatidylinositol 3-kinase signaling GO:0014065 9.32 ERBB2 PIK3CA
3 ERBB2 signaling pathway GO:0038128 9.26 ERBB2 PIK3CA
4 positive regulation of cell cycle arrest GO:0071158 9.16 BRCA1 TP53
5 vasculature development GO:0001944 8.96 FBXW7 PIK3CA
6 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 8.62 BRCA1 TP53

Molecular functions related to Uterine Corpus Serous Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 androgen receptor binding GO:0050681 8.96 BRCA1 CCNE1
2 ubiquitin protein ligase binding GO:0031625 8.8 BRCA1 FBXW7 TP53

Sources for Uterine Corpus Serous Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....